药易购(300937) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥924,379,178.84, representing a 13.72% increase year-over-year[5] - Net profit attributable to shareholders was ¥9,486,511.67, a significant increase of 357.93% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,084,081.10, up 262.25% year-over-year[5] - Total operating revenue for the period reached CNY 2,682,648,601.59, an increase from CNY 2,406,228,814.29 in the previous period, representing a growth of approximately 11.5%[18] - The company's net profit attributable to shareholders was CNY 191,403,283.84, up from CNY 174,625,319.88, indicating a growth of approximately 9.5%[18] - The net profit for Q3 2022 was CNY 9,424,419.53, a decrease of 25.4% compared to CNY 12,551,894.93 in Q3 2021[20] - The total profit before tax was CNY 14,443,992.45, a decrease from CNY 14,947,005.30 in the previous year[20] - The operating profit for Q3 2022 was CNY 14,495,605.36, a slight decrease from CNY 15,522,396.67 in the same period last year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,479,874,525.06, reflecting a 24.67% increase from the end of the previous year[5] - Current assets totaled CNY 1,131,433,922.71 as of September 30, 2022, compared to CNY 831,684,671.94 at the beginning of the year, marking an increase of around 36.1%[17] - The company's total assets reached CNY 1,479,874,525.06, up from CNY 1,187,068,605.90, representing a growth of approximately 24.6%[17] - The total liabilities increased to CNY 668,520,864.57 from CNY 399,131,979.12, showing a significant rise of approximately 67.5%[17] - Short-term borrowings increased to CNY 154,180,765.23 from CNY 119,358,790.60, reflecting a rise of about 29.2%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,421[11] - The largest shareholder, Li Yanfei, holds 36.97% of the shares, totaling 35,370,000 shares[11] - The second-largest shareholder, Chengdu Hesen Investment Management Center, holds 7.11% with 6,800,000 shares[11] - The company has a total of 54,850,000 restricted shares remaining after the current period[15] - The company plans to release 100,000 restricted shares on December 21, 2022[15] - The top ten shareholders include four natural persons and six private investment partnerships[11] - The company has not disclosed any related party relationships among the top ten shareholders[11] - The total number of shares held by the top ten unrestricted shareholders is 6,750,000 shares[11] - The company has a lock-up period of 36 months for shares issued in the public offering[14] - The report indicates that there are no shareholders participating in margin trading[12] Research and Development - Research and development expenses for the year-to-date reached ¥13,096,920.83, attributed to the establishment of a new R&D center[9] - The company reported R&D expenses of CNY 13,096,920.83 for the period, highlighting its commitment to innovation and development[18] Cash Flow - The net cash flow from operating activities was CNY 28,978,498.23, a significant improvement from a negative cash flow of CNY -173,221,674.20 in the same period last year[22] - The company reported a net cash outflow from investing activities of CNY -18,791,341.52, an improvement from CNY -34,098,623.56 in Q3 2021[22] - The net cash flow from financing activities was CNY 33,052,442.00, down from CNY 223,989,522.76 in the previous year[22] - The total cash and cash equivalents at the end of the period were CNY 178,364,944.89, an increase from CNY 110,329,420.79 at the end of Q3 2021[22] Financial Expenses - Financial expenses surged by 437.87% to ¥4,010,266.03, driven by increased interest costs from bank loans[9]